Pathology: non squamous - mNSCLC - L1 - all population;
| non squamous - mNSCLC - L1 - all population | ||||
| IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 | IMpower-130 (all population), 2019 | IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 2018 | ||
| atezolizumab plus carboplatin plus nab-paclitaxel | 1 | T1T0 | ||
| atezolizumab plus bevacizumab plus carboplatin plus paclitaxel | 1 | T1 | ||
| atezolizumab plus carboplatin plus paclitaxel | 1 | T1 | ||
| bevacizumab plus carboplatin and paclitaxel | 0 | T0 | T0 | |